Bhringraj — Benefits Deep Dive

Bhringraj — Eclipta prostrata, labelled Eclipta alba almost everywhere — is Ayurveda's designated hair drug, kesharaja, "king of hair". It is also, of all the herbal hair claims examined on this site, the one with the most specific preclinical case behind it. That is worth stating plainly at the top, because the usual pattern for a herbal hair remedy is an antioxidant assay stretched into an argument. This is not that. Rodent studies applied the extract to skin, counted the days to regrowth, and used minoxidil as the comparator — the real drug, in something close to the right outcome. In a shaved-mouse model and a testosterone-induced alopecia model, the extract reached hair-growth initiation and completion faster than the minoxidil arm.

And there is still no adequate controlled human trial. Not a failed one — an absent one. Nobody has randomised people to a standardised bhringraj preparation, applied it to scalps, counted hairs in a marked target area at 24 weeks, and compared it against a vehicle. Every instrument that would be needed exists and is in routine use; a neighbouring herb, rosemary, was put through very nearly that trial. The tools were simply never pointed at this plant.

These four pages take that seriously in both directions. They report the animal work accurately rather than dismissing it, then specify exactly what would settle the question, label every citation with the species and preparation it used, and separate what is untested from what is refuted — because the greying claim, unlike the growth claim, runs against known biology rather than merely lacking data.

Deep-Dive Articles

Table of Contents

1. Deep-Dive Articles
2. Evidence Ledger: What Is Actually Known
3. How to Read This Leg
4. Key Research: Hair Growth and Greying
5. Key Research: Species, Chemistry and Authentication
6. Key Research: Liver and Anti-Inflammatory Pharmacology
7. Key Research: Safety, Allergy and Contamination
8. Key Research: Comparators That Do Have Human Trials
9. External Resources
10. Connections

Evidence Ledger: What Is Actually Known

Ranked by how well established each item is — deliberately not in the order the marketing puts them — and distinguishing absent (never tested) from negative (tested and failed), because collapsing those two verdicts always flatters the untested claim.

• Chemistry — established. The coumestans wedelolactone and demethylwedelolactone, plus ecliptasaponins and eclalbasaponins, luteolin, apigenin, sterols and root thiophenes. Not in dispute.
• Molecular pharmacology — established in vitro. Wedelolactone inhibits the IKK complex upstream of NF-κB, inhibits 5-lipoxygenase, and inhibits secretory phospholipase A2. Three independent anti-inflammatory routes, all in cell-free or cell-culture systems.
• Safety by usage history — well supported. A long food and topical record, no notable toxicity signal, no documented hepatotoxicity. The firmest practical statements about this plant are safety statements.
• Hair growth in animals — supported. Topical extract shortened time to hair-growth initiation and completion in shaved rodents and in a testosterone-induced alopecia model, versus a minoxidil arm. Two models, and a genuinely direct comparison.
• Liver protection in animals — supported, with a caveat. Consistent across independent groups against carbon tetrachloride, paracetamol and ethanol — but the designs are overwhelmingly pre-treatment, which models prevention of an acute poisoning rather than treatment of established disease.
• Snake-venom phospholipase A2 neutralisation — supported in rodents, and clinically irrelevant. Interesting pharmacology, and not a basis for human use: snakebite is a time-critical emergency, antivenom is the only treatment, and neurotoxic venom components are untouched by this mechanism.
• Bleeding effects — contradictory. A traditional haemostatic indication alongside an in vitro literature that disagrees with itself on platelets and coagulation. Unresolved direction of effect, which is why the caution is around surgery and blood thinners rather than confidence either way.
• Hair growth in humans — absent. No randomised, controlled, adequately powered trial of this plant alone, for any form of hair loss.
• Any human liver measure — absent. No trial for hepatitis, fatty liver, cirrhosis or raised transaminases.
• Human pharmacokinetics — absent, and this is the hinge. Nobody knows whether an oral dose or a scalp oil delivers wedelolactone anywhere near the concentrations at which it works in a dish.
• Polyherbal Ayurvedic liver formula in alcoholic liver disease — negative. Randomised human trials exist, the best-known result was no benefit, and the product tested does not contain Eclipta. Reported here because it removes the "traditional medicine cannot be trialled" defence entirely.
• Reversing grey hair — not supported at any tier. Greying is melanocyte stem-cell depletion and the hair shaft is dead keratin, so there is nothing left to stimulate and nothing living to repigment. The plant's blue-black sap does stain hair; that is a dye and it washes out.

Read the ledger top to bottom and the shape is clear: the best-established facts about bhringraj are a chemistry fact and a safety fact. The reason people buy it sits in the middle, supported in animals. The claim it is most aggressively marketed for — reversing grey — is at the bottom, and is the only item here that is contradicted rather than merely untested.

How to Read This Leg

Four habits are applied consistently across these pages, and they are worth naming so the reasoning can be checked rather than taken on trust.

1. Every citation is labelled with its species, part, preparation and route. Borrowed evidence is the commonest way a herb page overstates itself, and one disclaimer at the top does not prevent it. Bhringraj needs this more than most herbs, because the trade name covers two genera and the marker compound occurs in both.
2. Absence of evidence is written as a finding. "No known interactions" means no interaction study exists; "no case reports" partly reflects nobody looking. Each page carries a numbered list of what is not known — the missing pharmacokinetics, the missing toxicology, the missing dose-finding — so unknowns are stated results rather than gaps a reader must infer from silence.
3. Where a claim is untested, the test is specified. Naming the endpoints and instruments — target-area hair counts, trichoscopy, MRI-PDFF, elastography — is stronger than any hedge, because it shows the tools exist and were never used. Where comparators have real human trials (rosemary for hair, silymarin for liver, Phyllanthus for hepatitis B), they are named.
4. Numbers that cannot be stood behind are refused, and the refusal is stated. No LD50, no human-equivalent dose, no contamination rate, no percentage improvements quoted second-hand from rodent papers. The same rule runs in the exculpatory direction: hazards this plant does not have are listed explicitly, because manufacturing a warning is as much an accuracy failure as omitting one.

On citations: every reference below links to a PubMed search, never to a numeric record. A mistyped identifier delivers a different paper — usually a neighbour in the same journal issue — and does so invisibly. A search always resolves, and the title, journal and year are given as plain text so they can be checked independently. Where metadata could not be verified, the finding is described and a topic search given instead, and that limitation is stated on the page.

Key Research: Hair Growth and Greying

1. Roy RK, Thakur M, Dixit VK. Hair growth promoting activity of Eclipta alba in male albino rats. Archives of Dermatological Research, 2008. Animal — E. alba, topical petroleum-ether and ethanol extracts.
2. Datta K, Singh AT, Mukherjee A, et al. Eclipta alba extract with potential for hair growth promoting activity. Journal of Ethnopharmacology, 2009. Animal — shaved-mouse and testosterone-induced models. The source of the "faster than minoxidil" line.
3. Müller-Röver S, Handjiski B, van der Veen C, et al. A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. Journal of Investigative Dermatology, 2001. Why rodent follicles cycle in synchronised waves, and why a timing endpoint is easy to move.
4. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology, 2004. Needed to interpret the comparator, including its sulfotransferase activation step.
5. Nishimura EK, Granter SR, Fisher DE. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science, 2005. Why topical repigmentation claims fail at the first hurdle.
6. Wood JM, Decker H, Hartmann H, et al. Senile hair graying: hydrogen peroxide-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB Journal, 2009.
7. Rele AS, Mohile RB. Effect of mineral oil, sunflower oil, and coconut oil on prevention of hair damage. Journal of Cosmetic Science, 2003. The carrier-oil effect a bhringraj oil trial would have to control for.
8. Hoffmann R. TrichoScan: combining epiluminescence microscopy with digital image analysis for the measurement of hair growth in vivo. European Journal of Dermatology, 2001. One of the instruments that exists and was never pointed at this plant.
9. Live search: Eclipta alopecia clinical trial — the search that should return a trial and does not.

Key Research: Species, Chemistry and Authentication

1. Wagner H, Geyer B, Kiso Y, Hikino H, Rao GS. Coumestans as the main active principles of the liver drugs Eclipta alba and Wedelia calendulacea. Planta Medica, 1986. One paper, two genera, one shared marker compound — which is why a wedelolactone assay is a potency check and not an identity check.
2. Live search: all three Eclipta binomials at once — a single-name search misses roughly half the literature.
3. Live search: peela bhringraj under all three of its names — a separate literature, and not evidence about Eclipta.
4. Live search: wedelolactone and demethylwedelolactone.
5. Live search: eclalbasaponins and ecliptasaponins — the saponin fraction, poorly absorbed as a class.
6. Live search: DNA barcoding for herbal raw-drug authentication — the method that answers what chemistry cannot.
7. Live search: wedelolactone quantification and standardisation.
8. Live search: pyrrolizidine-alkaloid distribution within Asteraceae — the basis for clearing Eclipta of the family's famous hazard.

Key Research: Liver and Anti-Inflammatory Pharmacology

1. Wagner H, Fessler B. In vitro 5-lipoxygenase inhibition by Eclipta alba extracts and the coumestan derivative wedelolactone. Planta Medica, 1986. In vitro.
2. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death and Differentiation; find on PubMed. In vitro, isolated compound. The best-replicated molecular claim about the plant.
3. Saxena AK, Singh B, Anand KK. Hepatoprotective effects of Eclipta alba on subcellular levels in rats. Journal of Ethnopharmacology, 1993. Animal. Representative of the template the whole literature follows.
4. de Silva HA, Saparamadu PA, Thabrew MI, et al. Liv.52 in alcoholic liver disease: a randomized controlled trial. Journal of Ethnopharmacology, 2003. Human, randomised — negative, and for a formula that does not contain Eclipta.
5. Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology, 2014. Context for the supplement category — in which Eclipta is not a named offender.
6. Live search: the full Eclipta hepatoprotection literature — note how uniformly the designs are pre-treatment.
7. Live search: wedelolactone and hepatic stellate cells.
8. Live search: how liver trials are actually measured — the endpoints never applied to this plant.

Key Research: Safety, Allergy and Contamination

1. Saper RB, Kales SN, Paquin J, et al. Heavy metal content of ayurvedic herbal medicine products. JAMA, 2004.
2. Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA, 2008. With the first, the basis of the contamination warning — stated qualitatively, because no single rate describes the category today.
3. Paulsen E. Contact sensitization from Compositae-containing herbal remedies and cosmetics. Contact Dermatitis, find on PubMed. The realistic adverse event for a repeatedly applied Asteraceae oil.
4. Melo PA, Ownby CL. Ability of wedelolactone, heparin and para-bromophenacyl bromide to antagonize the myotoxic effects of two crotaline venoms. Toxicon, find on PubMed. Animal. Listed with the standing warning: snakebite is an emergency and antivenom is the treatment.
5. Live search: Eclipta and blood glucose in rodents — the basis of the antidiabetic-drug caution.
6. Live search: Eclipta and thyroid hormones in rodents — described on the safety page, not quoted; metadata unverified.
7. Live search: coumestans as phytoestrogens — a class-level caution almost nobody mentions.
8. Live search: α-terthienyl phototoxicity — a real laboratory property with no documented clinical event.
9. Live search: Eclipta pharmacokinetics — the gap that matters most, and it is empty.

Key Research: Comparators That Do Have Human Trials

Naming interventions with real trials pre-empts the argument that traditional remedies cannot be tested, and gives a reader a genuine alternative rather than a hedge.

1. Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A. Rosemary oil versus minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed, 2015. Human, randomised, no placebo arm — which is a real limitation, and still a tier above anything bhringraj has.
2. Live search: minoxidil and finasteride randomised trials — what tested hair-loss evidence looks like.
3. Live search: silymarin trials in liver disease — the positive control used in the rodent Eclipta studies, and the liver herb with human data.
4. Live search: Phyllanthus amarus and hepatitis B — a traditional Indian plant that accumulated real human trials, and what happened when replication was attempted.
5. Live search: premature greying, B12, ferritin and thyroid — the correctable causes worth ruling out before buying oils.
6. Live search: telogen effluvium and spontaneous recovery — why sincere testimonials are unreliable evidence in this field.

External Resources

• PubMed — the primary literature index used for every citation on these pages.
• ClinicalTrials.gov — check for any registered Eclipta trial before believing a "clinically proven" claim.
• NIH National Center for Complementary and Integrative Health — plain-language evidence summaries for herbs and supplements.
• LiverTox (NIH) — the reference database for drug- and herb-induced liver injury.
• MedlinePlus — patient-level information from the US National Library of Medicine.
• Plants of the World Online (Kew) — the authority for checking accepted names and synonyms, including the Eclipta / Sphagneticola tangle.
• American Academy of Dermatology — guidance on hair loss and scalp conditions.
• US FDA: Dietary Supplements — how supplements are regulated, and current safety communications.
• Ministry of Ayush, Government of India — the official source for Ayurvedic pharmacopoeial and regulatory material.
• World Health Organization — including snakebite envenoming, which WHO classes as a neglected tropical disease.

Connections

• All Herbs
• Bhringraj (Eclipta prostrata) — the main topic page: botany, both traditions, constituents, forms, dosage and cautions.
• Bhringraj for Hair Growth — the rodent evidence, the missing trial, and the greying question.
• Which Bhringraj? — species, look-alikes, and which plant each study used.
• Liver and Other Ayurvedic Uses — wedelolactone, NF-κB, and the polyherbal trap.
• Oils, Formulations and Safety — taila chemistry, patch testing, interactions, heavy metals.
• Curry Leaf: Hair and Skin — names bhringraj as the tradition's actual primary hair herb, and dismantles the backwards tyrosinase argument.
• Rosemary for Hair Loss — the botanical with a randomised human hair trial, and what that trial cannot show.
• Amla: Hair, Skin and Cosmetic Use — bhringraj's usual partner in Ayurvedic hair oils.
• Neem for Skin Conditions — the other great Ayurvedic skin-and-scalp plant, with a larger evidence base.
• Milk Thistle: Liver Protection — silymarin, the positive control in the rodent liver studies.
• Triphala Dosing and Safety — the polyherbal attribution problem worked through in detail.
• Ashwagandha Benefits — a useful contrast: an Ayurvedic rasayana that does have human trials.
• Alopecia — what actually causes hair loss and what has been shown to treat it.
• Contact Dermatitis — the realistic risk from a repeatedly applied Asteraceae oil.
• Non-Alcoholic Fatty Liver Disease — the condition most often self-treated with liver herbs.
• Liver Function Tests — how liver injury is actually measured.
• Ferritin — worth checking before spending money on hair oils.
• Lead — the metal most often found in contaminated Ayurvedic products.

These pages are educational and are not medical advice. Bhringraj is not a proven treatment for hair loss, grey hair or any liver condition: the evidence is traditional use plus animal and in vitro studies, and no adequate controlled human trial exists for any of those uses. Patch test any new oil before applying it to the whole scalp, avoid oral use in pregnancy, and speak to a clinician about persistent hair loss or abnormal liver tests rather than self-treating. Do not use this plant for snakebite — snakebite is a medical emergency and antivenom is the only treatment.

Back to Table of Contents